

Global Chemotherapy Drugs for Neuroblastoma Market Growth 2025-2031

<https://marketpublishers.com/r/G8A198C3FFE2EN.html>

Date: September 2025

Pages: 87

Price: US\$ 3,660.00 (Single User License)

ID: G8A198C3FFE2EN

Abstracts

The global Chemotherapy Drugs for Neuroblastoma market size is predicted to grow from US\$ 136 million in 2025 to US\$ 180 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.

Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.

United States market for Chemotherapy Drugs for Neuroblastoma is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Chemotherapy Drugs for Neuroblastoma is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Chemotherapy Drugs for Neuroblastoma is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Chemotherapy Drugs for Neuroblastoma players cover Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Chemotherapy Drugs for Neuroblastoma Industry Forecast” looks at past sales and reviews total world Chemotherapy Drugs for Neuroblastoma sales in 2024, providing a comprehensive analysis by region and market sector of projected Chemotherapy Drugs for Neuroblastoma sales for 2025 through 2031. With Chemotherapy Drugs for Neuroblastoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Chemotherapy Drugs for Neuroblastoma industry.

This Insight Report provides a comprehensive analysis of the global Chemotherapy Drugs for Neuroblastoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chemotherapy Drugs for Neuroblastoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Chemotherapy Drugs for Neuroblastoma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chemotherapy Drugs for Neuroblastoma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chemotherapy Drugs for Neuroblastoma.

This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Drugs for Neuroblastoma market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Cyclophosphamide

Cisplatin or Carboplatin

Vincristine

Doxorubicin (Adriamycin)

Etoposide

Other

Segmentation by Application:

Hospital

Clinic

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Baxter Healthcare

Ingenus Pharmaceuticals

ANI Pharmaceuticals

Teva Pharmaceuticals

Qilu Pharmaceutical

Pfizer

Hikma Pharmaceuticals

Fresenius Kabi

Accord Healthcare

Viartis

Key Questions Addressed in this Report

What is the 10-year outlook for the global Chemotherapy Drugs for Neuroblastoma market?

What factors are driving Chemotherapy Drugs for Neuroblastoma market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Chemotherapy Drugs for Neuroblastoma market opportunities vary by end market size?

How does Chemotherapy Drugs for Neuroblastoma break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Chemotherapy Drugs for Neuroblastoma Annual Sales 2020-2031
- 2.1.2 World Current & Future Analysis for Chemotherapy Drugs for Neuroblastoma by Geographic Region, 2020, 2024 & 2031
- 2.1.3 World Current & Future Analysis for Chemotherapy Drugs for Neuroblastoma by Country/Region, 2020, 2024 & 2031

2.2 Chemotherapy Drugs for Neuroblastoma Segment by Type

- 2.2.1 Cyclophosphamide
- 2.2.2 Cisplatin or Carboplatin
- 2.2.3 Vincristine
- 2.2.4 Doxorubicin (Adriamycin)
- 2.2.5 Etoposide
- 2.2.6 Other

2.3 Chemotherapy Drugs for Neuroblastoma Sales by Type

- 2.3.1 Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
- 2.3.2 Global Chemotherapy Drugs for Neuroblastoma Revenue and Market Share by Type (2020-2025)
- 2.3.3 Global Chemotherapy Drugs for Neuroblastoma Sale Price by Type (2020-2025)

2.4 Chemotherapy Drugs for Neuroblastoma Segment by Application

- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.4.3 Other

2.5 Chemotherapy Drugs for Neuroblastoma Sales by Application

2.5.1 Global Chemotherapy Drugs for Neuroblastoma Sale Market Share by Application (2020-2025)

2.5.2 Global Chemotherapy Drugs for Neuroblastoma Revenue and Market Share by Application (2020-2025)

2.5.3 Global Chemotherapy Drugs for Neuroblastoma Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Chemotherapy Drugs for Neuroblastoma Breakdown Data by Company

3.1.1 Global Chemotherapy Drugs for Neuroblastoma Annual Sales by Company (2020-2025)

3.1.2 Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Company (2020-2025)

3.2 Global Chemotherapy Drugs for Neuroblastoma Annual Revenue by Company (2020-2025)

3.2.1 Global Chemotherapy Drugs for Neuroblastoma Revenue by Company (2020-2025)

3.2.2 Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Company (2020-2025)

3.3 Global Chemotherapy Drugs for Neuroblastoma Sale Price by Company

3.4 Key Manufacturers Chemotherapy Drugs for Neuroblastoma Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Chemotherapy Drugs for Neuroblastoma Product Location Distribution

3.4.2 Players Chemotherapy Drugs for Neuroblastoma Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR CHEMOTHERAPY DRUGS FOR NEUROBLASTOMA BY GEOGRAPHIC REGION

4.1 World Historic Chemotherapy Drugs for Neuroblastoma Market Size by Geographic Region (2020-2025)

4.1.1 Global Chemotherapy Drugs for Neuroblastoma Annual Sales by Geographic Region (2020-2025)

- 4.1.2 Global Chemotherapy Drugs for Neuroblastoma Annual Revenue by Geographic Region (2020-2025)
- 4.2 World Historic Chemotherapy Drugs for Neuroblastoma Market Size by Country/Region (2020-2025)
 - 4.2.1 Global Chemotherapy Drugs for Neuroblastoma Annual Sales by Country/Region (2020-2025)
 - 4.2.2 Global Chemotherapy Drugs for Neuroblastoma Annual Revenue by Country/Region (2020-2025)
- 4.3 Americas Chemotherapy Drugs for Neuroblastoma Sales Growth
- 4.4 APAC Chemotherapy Drugs for Neuroblastoma Sales Growth
- 4.5 Europe Chemotherapy Drugs for Neuroblastoma Sales Growth
- 4.6 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Growth

5 AMERICAS

- 5.1 Americas Chemotherapy Drugs for Neuroblastoma Sales by Country
 - 5.1.1 Americas Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025)
 - 5.1.2 Americas Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025)
- 5.2 Americas Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
- 5.3 Americas Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Chemotherapy Drugs for Neuroblastoma Sales by Region
 - 6.1.1 APAC Chemotherapy Drugs for Neuroblastoma Sales by Region (2020-2025)
 - 6.1.2 APAC Chemotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025)
- 6.2 APAC Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
- 6.3 APAC Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia

- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Chemotherapy Drugs for Neuroblastoma by Country
 - 7.1.1 Europe Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025)
 - 7.1.2 Europe Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025)
- 7.2 Europe Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
- 7.3 Europe Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Chemotherapy Drugs for Neuroblastoma by Country
 - 8.1.1 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025)
 - 8.1.2 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025)
- 8.2 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
- 8.3 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Chemotherapy Drugs for Neuroblastoma

10.3 Manufacturing Process Analysis of Chemotherapy Drugs for Neuroblastoma

10.4 Industry Chain Structure of Chemotherapy Drugs for Neuroblastoma

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Chemotherapy Drugs for Neuroblastoma Distributors

11.3 Chemotherapy Drugs for Neuroblastoma Customer

12 WORLD FORECAST REVIEW FOR CHEMOTHERAPY DRUGS FOR NEUROBLASTOMA BY GEOGRAPHIC REGION

12.1 Global Chemotherapy Drugs for Neuroblastoma Market Size Forecast by Region

12.1.1 Global Chemotherapy Drugs for Neuroblastoma Forecast by Region (2026-2031)

12.1.2 Global Chemotherapy Drugs for Neuroblastoma Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global Chemotherapy Drugs for Neuroblastoma Forecast by Type (2026-2031)

12.7 Global Chemotherapy Drugs for Neuroblastoma Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Baxter Healthcare

13.1.1 Baxter Healthcare Company Information

13.1.2 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

- 13.1.3 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
- 13.1.4 Baxter Healthcare Main Business Overview
- 13.1.5 Baxter Healthcare Latest Developments
- 13.2 Ingenus Pharmaceuticals
 - 13.2.1 Ingenus Pharmaceuticals Company Information
 - 13.2.2 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
 - 13.2.3 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.2.4 Ingenus Pharmaceuticals Main Business Overview
 - 13.2.5 Ingenus Pharmaceuticals Latest Developments
- 13.3 ANI Pharmaceuticals
 - 13.3.1 ANI Pharmaceuticals Company Information
 - 13.3.2 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
 - 13.3.3 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.3.4 ANI Pharmaceuticals Main Business Overview
 - 13.3.5 ANI Pharmaceuticals Latest Developments
- 13.4 Teva Pharmaceuticals
 - 13.4.1 Teva Pharmaceuticals Company Information
 - 13.4.2 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
 - 13.4.3 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.4.4 Teva Pharmaceuticals Main Business Overview
 - 13.4.5 Teva Pharmaceuticals Latest Developments
- 13.5 Qilu Pharmaceutical
 - 13.5.1 Qilu Pharmaceutical Company Information
 - 13.5.2 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications
 - 13.5.3 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.5.4 Qilu Pharmaceutical Main Business Overview
 - 13.5.5 Qilu Pharmaceutical Latest Developments
- 13.6 Pfizer
 - 13.6.1 Pfizer Company Information
 - 13.6.2 Pfizer Chemotherapy Drugs for Neuroblastoma Product Portfolios and

Specifications

13.6.3 Pfizer Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)

13.6.4 Pfizer Main Business Overview

13.6.5 Pfizer Latest Developments

13.7 Hikma Pharmaceuticals

13.7.1 Hikma Pharmaceuticals Company Information

13.7.2 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product

Portfolios and Specifications

13.7.3 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)

13.7.4 Hikma Pharmaceuticals Main Business Overview

13.7.5 Hikma Pharmaceuticals Latest Developments

13.8 Fresenius Kabi

13.8.1 Fresenius Kabi Company Information

13.8.2 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

13.8.3 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)

13.8.4 Fresenius Kabi Main Business Overview

13.8.5 Fresenius Kabi Latest Developments

13.9 Accord Healthcare

13.9.1 Accord Healthcare Company Information

13.9.2 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

13.9.3 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 Accord Healthcare Main Business Overview

13.9.5 Accord Healthcare Latest Developments

13.10 Viatris

13.10.1 Viatris Company Information

13.10.2 Viatris Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

13.10.3 Viatris Chemotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin (2020-2025)

13.10.4 Viatris Main Business Overview

13.10.5 Viatris Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Chemotherapy Drugs for Neuroblastoma Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Chemotherapy Drugs for Neuroblastoma Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of Cyclophosphamide

Table 4. Major Players of Cisplatin or Carboplatin

Table 5. Major Players of Vincristine

Table 6. Major Players of Doxorubicin (Adriamycin)

Table 7. Major Players of Etoposide

Table 8. Major Players of Other

Table 9. Global Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)

Table 10. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)

Table 11. Global Chemotherapy Drugs for Neuroblastoma Revenue by Type (2020-2025) & (\$ million)

Table 12. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2020-2025)

Table 13. Global Chemotherapy Drugs for Neuroblastoma Sale Price by Type (2020-2025) & (US\$/Unit)

Table 14. Global Chemotherapy Drugs for Neuroblastoma Sale by Application (2020-2025) & (K Units)

Table 15. Global Chemotherapy Drugs for Neuroblastoma Sale Market Share by Application (2020-2025)

Table 16. Global Chemotherapy Drugs for Neuroblastoma Revenue by Application (2020-2025) & (\$ million)

Table 17. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2020-2025)

Table 18. Global Chemotherapy Drugs for Neuroblastoma Sale Price by Application (2020-2025) & (US\$/Unit)

Table 19. Global Chemotherapy Drugs for Neuroblastoma Sales by Company (2020-2025) & (K Units)

Table 20. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Company (2020-2025)

Table 21. Global Chemotherapy Drugs for Neuroblastoma Revenue by Company

(2020-2025) & (\$ millions)

Table 22. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Company (2020-2025)

Table 23. Global Chemotherapy Drugs for Neuroblastoma Sale Price by Company (2020-2025) & (US\$/Unit)

Table 24. Key Manufacturers Chemotherapy Drugs for Neuroblastoma Producing Area Distribution and Sales Area

Table 25. Players Chemotherapy Drugs for Neuroblastoma Products Offered

Table 26. Chemotherapy Drugs for Neuroblastoma Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 27. New Products and Potential Entrants

Table 28. Market M&A Activity & Strategy

Table 29. Global Chemotherapy Drugs for Neuroblastoma Sales by Geographic Region (2020-2025) & (K Units)

Table 30. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share Geographic Region (2020-2025)

Table 31. Global Chemotherapy Drugs for Neuroblastoma Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 32. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Geographic Region (2020-2025)

Table 33. Global Chemotherapy Drugs for Neuroblastoma Sales by Country/Region (2020-2025) & (K Units)

Table 34. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country/Region (2020-2025)

Table 35. Global Chemotherapy Drugs for Neuroblastoma Revenue by Country/Region (2020-2025) & (\$ millions)

Table 36. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Country/Region (2020-2025)

Table 37. Americas Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)

Table 38. Americas Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2025)

Table 39. Americas Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (\$ millions)

Table 40. Americas Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)

Table 41. Americas Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)

Table 42. APAC Chemotherapy Drugs for Neuroblastoma Sales by Region (2020-2025)

& (K Units)

Table 43. APAC Chemotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2025)

Table 44. APAC Chemotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025) & (\$ millions)

Table 45. APAC Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)

Table 46. APAC Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)

Table 47. Europe Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)

Table 48. Europe Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (\$ millions)

Table 49. Europe Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)

Table 50. Europe Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)

Table 51. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)

Table 52. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2025)

Table 53. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025) & (K Units)

Table 54. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2025) & (K Units)

Table 55. Key Market Drivers & Growth Opportunities of Chemotherapy Drugs for Neuroblastoma

Table 56. Key Market Challenges & Risks of Chemotherapy Drugs for Neuroblastoma

Table 57. Key Industry Trends of Chemotherapy Drugs for Neuroblastoma

Table 58. Chemotherapy Drugs for Neuroblastoma Raw Material

Table 59. Key Suppliers of Raw Materials

Table 60. Chemotherapy Drugs for Neuroblastoma Distributors List

Table 61. Chemotherapy Drugs for Neuroblastoma Customer List

Table 62. Global Chemotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2031) & (K Units)

Table 63. Global Chemotherapy Drugs for Neuroblastoma Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 64. Americas Chemotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2031) & (K Units)

Table 65. Americas Chemotherapy Drugs for Neuroblastoma Annual Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 66. APAC Chemotherapy Drugs for Neuroblastoma Sales Forecast by Region (2026-2031) & (K Units)

Table 67. APAC Chemotherapy Drugs for Neuroblastoma Annual Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 68. Europe Chemotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2031) & (K Units)

Table 69. Europe Chemotherapy Drugs for Neuroblastoma Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 70. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Forecast by Country (2026-2031) & (K Units)

Table 71. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 72. Global Chemotherapy Drugs for Neuroblastoma Sales Forecast by Type (2026-2031) & (K Units)

Table 73. Global Chemotherapy Drugs for Neuroblastoma Revenue Forecast by Type (2026-2031) & (\$ millions)

Table 74. Global Chemotherapy Drugs for Neuroblastoma Sales Forecast by Application (2026-2031) & (K Units)

Table 75. Global Chemotherapy Drugs for Neuroblastoma Revenue Forecast by Application (2026-2031) & (\$ millions)

Table 76. Baxter Healthcare Basic Information, Chemotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 77. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 78. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 79. Baxter Healthcare Main Business

Table 80. Baxter Healthcare Latest Developments

Table 81. Ingenus Pharmaceuticals Basic Information, Chemotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 82. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 83. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 84. Ingenus Pharmaceuticals Main Business

Table 85. Ingenus Pharmaceuticals Latest Developments

Table 86. ANI Pharmaceuticals Basic Information, Chemotherapy Drugs for

Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 87. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 88. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 89. ANI Pharmaceuticals Main Business

Table 90. ANI Pharmaceuticals Latest Developments

Table 91. Teva Pharmaceuticals Basic Information, Chemotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 92. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 93. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 94. Teva Pharmaceuticals Main Business

Table 95. Teva Pharmaceuticals Latest Developments

Table 96. Qilu Pharmaceutical Basic Information, Chemotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 97. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 98. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 99. Qilu Pharmaceutical Main Business

Table 100. Qilu Pharmaceutical Latest Developments

Table 101. Pfizer Basic Information, Chemotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 102. Pfizer Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 103. Pfizer Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 104. Pfizer Main Business

Table 105. Pfizer Latest Developments

Table 106. Hikma Pharmaceuticals Basic Information, Chemotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 107. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 108. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 109. Hikma Pharmaceuticals Main Business

Table 110. Hikma Pharmaceuticals Latest Developments

Table 111. Fresenius Kabi Basic Information, Chemotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 112. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 113. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 114. Fresenius Kabi Main Business

Table 115. Fresenius Kabi Latest Developments

Table 116. Accord Healthcare Basic Information, Chemotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 117. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 118. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 119. Accord Healthcare Main Business

Table 120. Accord Healthcare Latest Developments

Table 121. Viatris Basic Information, Chemotherapy Drugs for Neuroblastoma Manufacturing Base, Sales Area and Its Competitors

Table 122. Viatris Chemotherapy Drugs for Neuroblastoma Product Portfolios and Specifications

Table 123. Viatris Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 124. Viatris Main Business

Table 125. Viatris Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Chemotherapy Drugs for Neuroblastoma

Figure 2. Chemotherapy Drugs for Neuroblastoma Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Chemotherapy Drugs for Neuroblastoma Sales Growth Rate 2020-2031 (K Units)

Figure 7. Global Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate 2020-2031 (\$ millions)

Figure 8. Chemotherapy Drugs for Neuroblastoma Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Figure 9. Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country/Region (2024)

Figure 10. Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country/Region (2020, 2024 & 2031)

Figure 11. Product Picture of Cyclophosphamide

Figure 12. Product Picture of Cisplatin or Carboplatin

Figure 13. Product Picture of Vincristine

Figure 14. Product Picture of Doxorubicin (Adriamycin)

Figure 15. Product Picture of Etoposide

Figure 16. Product Picture of Other

Figure 17. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type in 2025

Figure 18. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2020-2025)

Figure 19. Chemotherapy Drugs for Neuroblastoma Consumed in Hospital

Figure 20. Global Chemotherapy Drugs for Neuroblastoma Market: Hospital (2020-2025) & (K Units)

Figure 21. Chemotherapy Drugs for Neuroblastoma Consumed in Clinic

Figure 22. Global Chemotherapy Drugs for Neuroblastoma Market: Clinic (2020-2025) & (K Units)

Figure 23. Chemotherapy Drugs for Neuroblastoma Consumed in Other

Figure 24. Global Chemotherapy Drugs for Neuroblastoma Market: Other (2020-2025) & (K Units)

Figure 25. Global Chemotherapy Drugs for Neuroblastoma Sale Market Share by

Application (2024)

Figure 26. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Application in 2025

Figure 27. Chemotherapy Drugs for Neuroblastoma Sales by Company in 2025 (K Units)

Figure 28. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Company in 2025

Figure 29. Chemotherapy Drugs for Neuroblastoma Revenue by Company in 2025 (\$ millions)

Figure 30. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Company in 2025

Figure 31. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Geographic Region (2020-2025)

Figure 32. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Geographic Region in 2025

Figure 33. Americas Chemotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)

Figure 34. Americas Chemotherapy Drugs for Neuroblastoma Revenue 2020-2025 (\$ millions)

Figure 35. APAC Chemotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)

Figure 36. APAC Chemotherapy Drugs for Neuroblastoma Revenue 2020-2025 (\$ millions)

Figure 37. Europe Chemotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)

Figure 38. Europe Chemotherapy Drugs for Neuroblastoma Revenue 2020-2025 (\$ millions)

Figure 39. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales 2020-2025 (K Units)

Figure 40. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Revenue 2020-2025 (\$ millions)

Figure 41. Americas Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2025

Figure 42. Americas Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2025)

Figure 43. Americas Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)

Figure 44. Americas Chemotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)

Figure 45. United States Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 46. Canada Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 47. Mexico Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 48. Brazil Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 49. APAC Chemotherapy Drugs for Neuroblastoma Sales Market Share by Region in 2025

Figure 50. APAC Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2025)

Figure 51. APAC Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)

Figure 52. APAC Chemotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)

Figure 53. China Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 54. Japan Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 55. South Korea Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 56. Southeast Asia Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 57. India Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 58. Australia Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 59. China Taiwan Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 60. Europe Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country in 2025

Figure 61. Europe Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2025)

Figure 62. Europe Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)

Figure 63. Europe Chemotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)

Figure 64. Germany Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 65. France Chemotherapy Drugs for Neuroblastoma Revenue Growth

2020-2025 (\$ millions)

Figure 66. UK Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 67. Italy Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 68. Russia Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 69. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2025)

Figure 70. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)

Figure 71. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)

Figure 72. Egypt Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 73. South Africa Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 74. Israel Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 75. Turkey Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 76. GCC Countries Chemotherapy Drugs for Neuroblastoma Revenue Growth 2020-2025 (\$ millions)

Figure 77. Manufacturing Cost Structure Analysis of Chemotherapy Drugs for Neuroblastoma in 2025

Figure 78. Manufacturing Process Analysis of Chemotherapy Drugs for Neuroblastoma

Figure 79. Industry Chain Structure of Chemotherapy Drugs for Neuroblastoma

Figure 80. Channels of Distribution

Figure 81. Global Chemotherapy Drugs for Neuroblastoma Sales Market Forecast by Region (2026-2031)

Figure 82. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share Forecast by Region (2026-2031)

Figure 83. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share Forecast by Type (2026-2031)

Figure 84. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share Forecast by Type (2026-2031)

Figure 85. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share Forecast by Application (2026-2031)

Figure 86. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share

Forecast by Application (2026-2031)

I would like to order

Product name: Global Chemotherapy Drugs for Neuroblastoma Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G8A198C3FFE2EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8A198C3FFE2EN.html>